Respiratory

Back to articles

Inhaled corticosteroids: Risks outweigh benefit in COPD

KEY POINT

The benefit of adding an inhaled corticosteroid (ICS) to a long-acting beta-2 agonist (LABA) in patients with chronic obstructive pulmonary disease (COPD) is limited; serious risks including increased incidence of pneumonia and other infections exist.